Fmr LLC Buys 86,712 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

FMR LLC increased its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 35.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 330,412 shares of the company's stock after purchasing an additional 86,712 shares during the period. FMR LLC owned 0.37% of NewAmsterdam Pharma worth $5,485,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. HealthInvest Partners AB lifted its holdings in shares of NewAmsterdam Pharma by 83.4% in the third quarter. HealthInvest Partners AB now owns 138,983 shares of the company's stock worth $2,307,000 after buying an additional 63,189 shares in the last quarter. Jennison Associates LLC lifted its stake in NewAmsterdam Pharma by 8.9% in the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company's stock worth $16,937,000 after purchasing an additional 83,115 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of NewAmsterdam Pharma by 79.9% during the 3rd quarter. GSA Capital Partners LLP now owns 66,402 shares of the company's stock valued at $1,102,000 after purchasing an additional 29,496 shares during the last quarter. Lisanti Capital Growth LLC purchased a new position in shares of NewAmsterdam Pharma during the third quarter valued at about $700,000. Finally, TimesSquare Capital Management LLC lifted its position in shares of NewAmsterdam Pharma by 3.7% in the third quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company's stock worth $4,237,000 after buying an additional 9,160 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Stock Down 2.4 %

NAMS traded down $0.59 during trading on Friday, reaching $24.50. The company had a trading volume of 1,306,298 shares, compared to its average volume of 364,085. NewAmsterdam Pharma has a 52 week low of $9.72 and a 52 week high of $27.29. The business has a 50 day simple moving average of $20.40 and a 200-day simple moving average of $18.68.

Insider Transactions at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of the company's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the sale, the insider now directly owns 11,778,760 shares of the company's stock, valued at $295,411,300.80. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 86,803 shares of company stock worth $1,755,307. 19.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on NAMS shares. Piper Sandler restated an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Royal Bank of Canada restated an "outperform" rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Needham & Company LLC reiterated a "buy" rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a report on Wednesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $36.20.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.